Diagnosis and stabilisation of familial chylomicronemia syndrome in two infants presenting with hypertriglyceridemia‐induced acute pancreatitis DOI Creative Commons
Oliver Heath, Brooke Allender, Joel Smith

et al.

JIMD Reports, Journal Year: 2024, Volume and Issue: 65(4), P. 239 - 248

Published: June 2, 2024

Familial chylomicronemia syndrome (FCS) is a rare disorder of triglyceride (TG) metabolism caused by loss function variants in one five known canonical genes involved chylomicron lipolysis and clearance-

Language: Английский

Remnant cholesterol, vascular risk, and prevention of atherosclerosis DOI
Xavier Pintó, Marta Fanlo‐Maresma, Virginia Esteve-Luque

et al.

Clínica e Investigación en Arteriosclerosis (English Edition), Journal Year: 2023, Volume and Issue: 35(4), P. 206 - 217

Published: July 1, 2023

Language: Английский

Citations

3
The GPIHBP1-LPL complex and its role in plasma triglyceride metabolism: Insights into chylomicronemia DOI Creative Commons

Shali Jiang,

Zhuoqun Ren,

Y. L. Yang

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 169, P. 115874 - 115874

Published: Nov. 9, 2023

GPIHBP1 is a protein found in the endothelial cells of capillaries that anchored by glycosylphosphatidylinositol and binds to high-density lipoproteins. attaches lipoprotein lipase (LPL), subsequently carrying enzyme anchoring it capillary lumen. Enabling lipid metabolism essential for marginalization lipoproteins alongside capillaries. Studies underscore significance transporting, stabilizing, aiding LPL. The intricate interplay between LPL has provided novel insights into chylomicronemia recent years. Mutations hindering formation or reducing efficiency GPIHBP1-LPL complex are central onset chylomicronemia. This review delves structural nuances interaction, consequences mutations leading chylomicronemia, cutting-edge advancements treatment.

Language: Английский

Citations

3
Advancements In Pharmacotherapy for Hyperlipidemia: A Comprehensive Review of Recent Drug Innovations and Clinical Outcomes DOI Open Access
Hrithik Dey,

Vatsala Agarwal,

MD Naushad Ali

et al.

Journal of Drug Delivery and Therapeutics, Journal Year: 2024, Volume and Issue: 14(4), P. 111 - 122

Published: April 15, 2024

Hyperlipidemia, characterized by elevated blood lipid levels, significantly contributes to cardiovascular diseases (CVDs), the leading cause of global mortality per World Health Organization (WHO). Studies reveal a 20-30% increase in coronary heart disease risk for every 1 mmol/L rise LDL-C levels. While statins are widely used, novel pharmacotherapeutic approaches necessary effective hyperlipidemia management and CVD reduction. Recent clinical trials demonstrate efficacy innovative drugs like proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors lowering levels reducing adverse events. These findings highlight potential new therapies enhance existing treatments hyperlipidemia. Additionally, safety evaluations emerging lipid-lowering agents address concerns about effects long-term risks. Despite progress, challenges persist refining treatment strategies ensuring equitable access advanced therapies, especially marginalized populations. Incorporating pharmacotherapies into current offers personalized efficient management. Continued research interdisciplinary collaborations vital advancing our understanding metabolism translating scientific discoveries improved patient outcomes health. Ongoing innovation investment tailored crucial better individuals at CVDs. Keywords: hyperlipidemia, pcsk9 inhibitors, bempedoic acid, evinacumab, inclisiran mipomersen, volanesorsen

Language: Английский

Citations

0
APOA1/C3/A4/A5 Gene Cluster at 11q23.3 and Lipid Metabolism Disorders: From Epigenetic Mechanisms to Clinical Practices DOI Creative Commons
Qianqian Xiao, Jing Wang, Luyun Wang

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(6), P. 1224 - 1224

Published: May 31, 2024

The APOA1/C3/A4/A5 cluster is an essential component in regulating lipoprotein metabolism and maintaining plasma lipid homeostasis. A genome-wide association analysis Mendelian randomization have revealed potential associations between genetic variants within this disorders, including hyperlipidemia cardiovascular events. An enhanced understanding of the complexity gene regulation has led to growing recognition regarding role epigenetic variation modulating expression. Intensive research into regulatory patterns will help increase our pathogenesis disorders facilitate development new therapeutic approaches. This review discusses biology how affects circulating lipoproteins current progress cluster.

Language: Английский

Citations

0
Diagnosis and stabilisation of familial chylomicronemia syndrome in two infants presenting with hypertriglyceridemia‐induced acute pancreatitis DOI Creative Commons
Oliver Heath, Brooke Allender, Joel Smith

et al.

JIMD Reports, Journal Year: 2024, Volume and Issue: 65(4), P. 239 - 248

Published: June 2, 2024

Familial chylomicronemia syndrome (FCS) is a rare disorder of triglyceride (TG) metabolism caused by loss function variants in one five known canonical genes involved chylomicron lipolysis and clearance-

Language: Английский

Citations

0